Authors:
BOWEN DT
GELLY K
HEPBURN M
KANZ L
BRUGGER W
DENZLINGER C
CULLIGAN D
Citation: Dt. Bowen et al., LOW RESPONSE RATE TO A CONTINUOUS SCHEDULE OF AMIFOSTINE FOR LOW-RISKMYELODYSPLASTIC PATIENTS, British Journal of Haematology, 102(1), 1998, pp. 344-344
Authors:
GRIMWADE D
GORMAN P
DUPREZ E
HOWE K
LANGABEER S
OLIVER F
WALKER H
CULLIGAN D
WATERS J
POMFRET M
GOLDSTONE A
BURNETT A
FREEMONT P
SHEER D
SOLOMON E
Citation: D. Grimwade et al., CHARACTERIZATION OF CRYPTIC REARRANGEMENTS AND VARIANT TRANSLOCATIONSIN ACUTE PROMYELOCYTIC LEUKEMIA, Blood, 90(12), 1997, pp. 4876-4885
Authors:
LIM SH
CULLIGAN D
COUZENS S
FISHER J
JOHN S
POLLARD P
BURNETT A
WHITTAKER J
Citation: Sh. Lim et al., MOLECULAR EVIDENCE FOR A COMMON LEUKEMIC PROGENITOR IN ACUTE MIXED LYMPHOID AND MYELOID-LEUKEMIA, British Journal of Haematology, 92(1), 1996, pp. 131-133
Authors:
BOWEN DT
CULLIGAN D
BEGUIN Y
KENDALL R
WILLIS N
Citation: Dt. Bowen et al., ESTIMATION OF EFFECTIVE AND TOTAL ERYTHROPOIESIS IN MYELODYSPLASIA USING SERUM TRANSFERRIN RECEPTOR AND ERYTHROPOIETIN CONCENTRATIONS, WITHAUTOMATED RETICULOCYTE PARAMETERS, Leukemia, 8(1), 1994, pp. 151-155
Authors:
TENNANT GB
ALSABAH AI
CULLIGAN D
BOWEN DT
JACOBS A
BURNETT AK
Citation: Gb. Tennant et al., IN-VITRO RESPONSE OF MYELOID PROGENITORS TO PHYTOHAEMAGGLUTIN AND INTERLEUKIN-2 IS RELATED TO SURVIVAL OF SOME MYELODYSPLASTIC PATIENTS, Experimental hematology, 21(8), 1993, pp. 1036-1036
Authors:
BOWEN D
YANCIK S
BENNETT L
CULLIGAN D
RESSER K
Citation: D. Bowen et al., SERUM STEM-CELL FACTOR CONCENTRATION IN PATIENTS WITH MYELODYSPLASTICSYNDROMES, British Journal of Haematology, 85(1), 1993, pp. 63-66